Onodera, Y., Teramura, T., Takehara, T., Shigi, K
Immunogenicity testing follows a tiered approach: ECL or ELISA screening for ADA presence, competitive inhibition confirmatory assay, and cell-based neutralization assay for NAb characterization
Clinical assessments were conducted every 3 months to evaluate efficacy, measured as percentage of total weight loss (%TWL), excess weight loss (%EWL), changes in BMI, and improvement in comorbidities, as well as tolerance, monitored for adverse effects including gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea) and discontinuation rates
A healthy girl was born with a birth weight of 3606 grams, length of 50.5 cm, head circumference of 35.5 cm, and Apgar scores of 9, 9, and 10